Analyst Jessica Fye of J.P. Morgan reiterated a Buy rating on Alnylam Pharma, boosting the price target to $475.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jessica Fye’s rating is based on several compelling factors that highlight Alnylam Pharma’s promising future. The company has demonstrated exceptional performance in the second quarter, leading to an increase in sales projections for its TTR franchise. This strong performance, along with the guidance increase, suggests that there is potential for further growth. The analyst has set a year-end 2026 price target of $475, reflecting confidence in the company’s ability to exceed its updated guidance.
Furthermore, Alnylam’s transition towards profitability is notable, with expectations of earning more than $9 in non-GAAP EPS next year. The long-term outlook is also positive, with a forecasted increase in TTR franchise sales to $9.6 billion by 2035. The launch of Amvuttra in the ATTR-CM market is anticipated to be successful, supported by a proven platform and a promising pipeline. These factors, combined with the scarcity of stocks with such potential for significant upside, underpin the Buy rating.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $482.00 price target.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is neutral on the stock.